Endothelin, kidney disease, and hypertension.
作者信息
Speed Joshua S, Pollock David M
机构信息
Department of Medicine, Georgia Regents University, Section of Experimental Medicine, CB2200, 1459 Laney Walker Blvd, Augusta, GA 30912, USA.
出版信息
Hypertension. 2013 Jun;61(6):1142-5. doi: 10.1161/HYPERTENSIONAHA.113.00595. Epub 2013 Apr 22.
Abstract
摘要
相似文献
1
Endothelin, kidney disease, and hypertension.
Hypertension. 2013 Jun;61(6):1142-5. doi: 10.1161/HYPERTENSIONAHA.113.00595. Epub 2013 Apr 22.
2
Endothelin antagonism and hypertension: an evolving target.
Semin Nephrol. 2015 Mar;35(2):168-75. doi: 10.1016/j.semnephrol.2015.03.001.
3
Endothelin antagonists in hypertension and kidney disease.
Pediatr Nephrol. 2013 May;28(5):711-20. doi: 10.1007/s00467-012-2316-4. Epub 2012 Oct 16.
4
Endothelin receptors, renal effects and blood pressure.
Curr Opin Pharmacol. 2015 Apr;21:25-34. doi: 10.1016/j.coph.2014.12.007. Epub 2014 Dec 23.
5
Who's on first? Does hypertension in type I diabetics result from nephropathy or metabolic alterations?
Circulation. 2001 Jul 31;104(5):508-10. doi: 10.1161/01.cir.104.5.508.
6
Endothelin in hypertension: a role for receptor antagonists?
Cardiovasc Res. 1998 Sep;39(3):534-42. doi: 10.1016/s0008-6363(98)00154-0.
7
[Involvement of endothelin in the pathogenesis of hypertension and hypertensive target-organ damage].
Nihon Rinsho. 2004 Mar;62 Suppl 3:164-8.
8
Therapeutic potential of endothelin receptor antagonism in kidney disease.
Am J Physiol Regul Integr Comp Physiol. 2016 Mar 1;310(5):R388-97. doi: 10.1152/ajpregu.00478.2015. Epub 2015 Dec 23.
9
Endothelin antagonists and resistant hypertension in chronic kidney disease.
Curr Opin Nephrol Hypertens. 2010 Sep;19(5):432-6. doi: 10.1097/MNH.0b013e32833a7a25.
10
Novel receptor antagonists welcome a new era in endothelin biology.
Trends Pharmacol Sci. 1994 Sep;15(9):313-6. doi: 10.1016/0165-6147(94)90019-1.
引用本文的文献
1
The circadian clock protein PER1 is important in maintaining endothelin axis regulation in Dahl salt-sensitive rats.
Can J Physiol Pharmacol. 2023 Mar 1;101(3):136-146. doi: 10.1139/cjpp-2022-0134. Epub 2022 Nov 30.
2
Role of microRNAs and long non‑coding RNAs in glucocorticoid signaling (Review).
Int J Mol Med. 2022 Dec;50(6). doi: 10.3892/ijmm.2022.5203. Epub 2022 Nov 11.
3
Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice.
Can J Physiol Pharmacol. 2022 Jul 1;100(7):637-650. doi: 10.1139/cjpp-2022-0038. Epub 2022 Apr 12.
4
Plasma Levels of Big Endothelin-1 Are Associated with Renal Insufficiency and In-Hospital Mortality of Immune Thrombotic Thrombocytopenic Purpura.
Thromb Haemost. 2022 Mar;122(3):344-352. doi: 10.1055/a-1508-8347. Epub 2021 Jun 21.
5
Therapeutic Insights in Chronic Kidney Disease Progression.
Front Med (Lausanne). 2021 Feb 23;8:645187. doi: 10.3389/fmed.2021.645187. eCollection 2021.
6
Role of GRK4 in the regulation of the renal ETB receptor in hypertension.
FASEB J. 2020 Sep;34(9):11594-11604. doi: 10.1096/fj.201902552R. Epub 2020 Jul 20.
7
, A Novel Long Non-coding RNA Regulating Endothelin-1 in Human Proximal Tubule Cells.
Front Physiol. 2020 Mar 13;11:209. doi: 10.3389/fphys.2020.00209. eCollection 2020.
8
Unfavorable Reduction in the Ratio of Endothelin B to A Receptors in Experimental 5/6 Nephrectomy and Adenine Models of Chronic Renal Insufficiency.
Int J Mol Sci. 2020 Jan 31;21(3):936. doi: 10.3390/ijms21030936.
9
The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease.
Kidney Dis (Basel). 2020 Jan;6(1):22-34. doi: 10.1159/000504623. Epub 2019 Dec 18.
10
Protective Effects of Dexmedetomidine and Oxycodone in Patients Undergoing Limb Ischemia-Reperfusion.
Med Sci Monit. 2019 Nov 29;25:9073-9084. doi: 10.12659/MSM.918261.
本文引用的文献
1
Matrix metalloproteinase enhances big-endothelin-1 constriction in mesenteric vessels of pregnant rats with reduced uterine blood flow.
Hypertension. 2013 Feb;61(2):488-93. doi: 10.1161/HYPERTENSIONAHA.111.00055. Epub 2013 Jan 7.
2
CD36 and Na/K-ATPase-α1 form a proinflammatory signaling loop in kidney.
Hypertension. 2013 Jan;61(1):216-24. doi: 10.1161/HYPERTENSIONAHA.112.198770. Epub 2012 Nov 19.
3
Endothelin 1-dependent neurovascular dysfunction in chronic intermittent hypoxia.
Hypertension. 2012 Jul;60(1):106-13. doi: 10.1161/HYPERTENSIONAHA.112.193672. Epub 2012 Jun 11.
4
Oxidative stress contributes to sex differences in blood pressure in adult growth-restricted offspring.
Hypertension. 2012 Jul;60(1):114-22. doi: 10.1161/HYPERTENSIONAHA.112.192955. Epub 2012 May 14.
5
Linking placental ischemia and hypertension in preeclampsia: role of endothelin 1.
Hypertension. 2012 Aug;60(2):507-11. doi: 10.1161/HYPERTENSIONAHA.112.194845. Epub 2012 May 7.
6
Endothelin 1 activation of endothelin A receptor/NADPH oxidase pathway and diminished antioxidants critically contribute to endothelial progenitor cell reduction and dysfunction in salt-sensitive hypertension.
Hypertension. 2012 May;59(5):1037-43. doi: 10.1161/HYPERTENSIONAHA.111.183368. Epub 2012 Mar 19.
7
Ambrisentan and tadalafil synergistically relax endothelin-induced contraction of rat pulmonary arteries.
Hypertension. 2012 Mar;59(3):705-11. doi: 10.1161/HYPERTENSIONAHA.111.182261. Epub 2012 Feb 6.
8
Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.
Hypertension. 2012 Jan;59(1):151-7. doi: 10.1161/HYPERTENSIONAHA.111.182220. Epub 2011 Nov 28.
9
Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade.
PLoS One. 2011;6(10):e26063. doi: 10.1371/journal.pone.0026063. Epub 2011 Oct 7.
10
Chronic selective endothelin A receptor antagonism reduces serum uric acid in hypertensive chronic kidney disease.
Hypertension. 2011 Aug;58(2):e11-2. doi: 10.1161/HYPERTENSIONAHA.111.175646. Epub 2011 Jun 27.
Zotero 插件